Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

British Journal of Dermatology

Volumn 175, Issue 5, 2016, Pages 902-911

  Bissonnette, R ^a   Papp, K A ^b   Poulin, Y ^c   Gooderham, M ^d   Raman, M ^e   Mallbris, L ^f   Wang, C ^f   Purohit, V ^f   Mamolo, C ^f   Papacharalambous, J ^f   Ports, W C ^f  

^a INNOVADERM RESEARCH   (Canada)

^b K Papp Clinical Research and Probity Medical Research   (Canada)

^c Centre de Recherche Dermatologique du Quebec Metropolitain   (Canada)

^d SKiN Centre for Dermatology and Probity Medical Research Inc   (Canada)

^e Centre for Dermatology and Probity Medical Research   (Canada)

^f PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; TOFACITINIB; OINTMENT; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; ARTICLE; ATOPIC DERMATITIS; BODY SURFACE; BRONCHITIS; CONTACT DERMATITIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA AREA AND SEVERITY INDEX; FEMALE; FURUNCULOSIS; GASTROENTERITIS; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; LICHENOID ERUPTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MULTICENTER STUDY; OINTMENT; OPPORTUNISTIC INFECTION; PARALLEL DESIGN; PATIENT-REPORTED OUTCOME; PHASE 2 CLINICAL TRIAL; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE ASSESSMENT; SKIN IRRITATION; TREATMENT DURATION; VIRAL UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; CLINICAL TRIAL; DERMATITIS, ATOPIC; DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84989344281     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14871     Document Type: Article

References (33)

1. DaVeiga SP. Epidemiology of atopic dermatitis: a review. Allergy Asthma Proc 2012; 33:227–34.
2. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980; 92:44–7.
3. Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy 2014; 69:3–16.
4. Carroll CL, Balkrishnan R, Feldman SR et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005; 22:192–9.
5. Weisshaar E, Diepgen TL, Bruckner T et al. Itch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life, coping behaviour and SCORAD severity in 823 children. Acta Derm Venereol 2008; 88:234–9.
6. Eichenfield LF, Tom WL, Berger TG et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014; 71:116–32.
7. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005; 352:2314–24.
8. Ring J, Alomar A, Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26:1045–60.
9. Leung DY, Boguniewicz M, Howell MD et al. New insights into atopic dermatitis. J Clin Invest 2004; 113:651–7.
10. Howell MD, Parker ML, Mustelin T, Ranade K. Past, present, and future for biologic intervention in atopic dermatitis. Allergy 2015; 70:887–96.
11. Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT 2013; 2:e24137.
12. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003; 361:151–60.
13. Beck LA, Thaci D, Hamilton JD et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371:130–9.
14. Thaci D, Simpson EL, Beck LA et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016; 387:40–52.
15. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228:273–87.
16. Meyer DM, Jesson MI, Li X et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010; 7:41.
17. Krueger J, Suárez-Fariñas M, Fuentes-Duculan J et al. Pathologic immune pathways in psoriasis are rapidly attenuated by tofacitinib treatment. Br J Dermatol 2014; 171:e120.
18. Ports WC, Khan S, Lan S et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013; 169:137–45.
19. Papp KA, Menter A, Strober B et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167:668–77.
20. Bissonnette R, Iversen L, Sofen H et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol 2015; 172:1395–406.
21. Bachelez H, van de Kerkhof PC, Strohal R et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 2015; 386:552–61.
22. Papp KA, Menter MA, Abe M et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomised, placebo-controlled, phase III trials. Br J Dermatol 2015; 173:949–61.
23. Cochran WG. Some methods of strengthening the common X2 tests. Biometrics 1954; 10:417–51.
24. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719–48.
25. Ghoreschi K, Jesson MI, Li X et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011; 186:4234–43.
26. O'Sullivan LA, Liongue C, Lewis RS et al. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol 2007; 44:2497–506.
27. Cornelissen C, Lüscher-Firzlaff J, Baron JM, Lüscher B. Signaling by IL-31 and functional consequences. Eur J Cell Biol 2012; 91:552–66.
28. Sonkoly E, Muller A, Lauerma AI et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117:411–17.
29. Fukuyama T, Ehling S, Cook E, Baumer W. Topically administered Janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis. J Pharmacol Exp Ther 2015; 354:394–405.
30. Romeo SP. Atopic dermatitis: the itch that rashes. Pediatr Nurs 1995; 21:157–63.
31. Weisshaar E, Apfelbacher C, Jäger G et al. Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br J Dermatol 2006; 155:957–64.
32. Nelson AA, Miller AD, Fleischer AB et al. How much of a topical agent should be prescribed for children of different sizes? J Dermatolog Treat 2006; 17:224–8.
33. Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 2015; 73:395–9.